Cimeio Therapeutics

Cimeio Therapeutics is developing a groundbreaking platform that pairs gene-edited, 'shielded' cells with potent immunotherapies to create curative treatments for hematologic diseases. Its core innovation involves editing cell surface proteins to maintain function while making them invisible to paired therapies like antibodies, ADCs, and CAR-T cells, allowing for targeted conditioning and disease eradication. The company has validated its approach with a high-profile Nature publication and secured a significant partnership with Kyowa Kirin valued at up to $300 million, positioning it as a leader in next-generation cell and gene therapies.

Shielded-Cell & Immunotherapy Pairs™ (SCIP): A platform that uses gene editing to create epitope-shielded hematopoietic stem cells resistant to depletion by paired, potent immunotherapies (ADCs, antibodies, CAR-T), enabling targeted elimination of diseased cells while protecting healthy ones.

Cimeio competes with traditional transplant conditioning approaches, gene editing companies focused on genetic diseases (e.g., CRISPR Therapeutics), and developers of targeted blood cancer therapies. Its key differentiation is the SCIP platform's ability to make previously undruggable pan-hematopoietic targets like CD45 viable, creating a potentially universal approach to treating blood cancers while protecting healthy hematopoiesis.